Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? / Deacon, Carolyn F; Ahrén, Bo; Holst, Jens J.

In: Expert Opinion on Investigational Drugs, Vol. 13, No. 9, 2004, p. 1091-102.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Deacon, CF, Ahrén, B & Holst, JJ 2004, 'Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?', Expert Opinion on Investigational Drugs, vol. 13, no. 9, pp. 1091-102. https://doi.org/10.1517/13543784.13.9.1091

APA

Deacon, C. F., Ahrén, B., & Holst, J. J. (2004). Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opinion on Investigational Drugs, 13(9), 1091-102. https://doi.org/10.1517/13543784.13.9.1091

Vancouver

Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opinion on Investigational Drugs. 2004;13(9):1091-102. https://doi.org/10.1517/13543784.13.9.1091

Author

Deacon, Carolyn F ; Ahrén, Bo ; Holst, Jens J. / Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. In: Expert Opinion on Investigational Drugs. 2004 ; Vol. 13, No. 9. pp. 1091-102.

Bibtex

@article{023a1cd0ab4c11ddb5e9000ea68e967b,
title = "Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?",
abstract = "Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabetologists and the pharmaceutical industry alike, as they may become established as the next member of the oral antidiabetic class of therapeutic agents, designed to lower blood glucose and, possibly, prevent the progressive impairment of glucose metabolism in patients with impaired glucose tolerance and Type 2 diabetes. DPP IV has become a focus of attention for drug design, as it has a pivotal role in the rapid degradation of at least two of the hormones released during food ingestion, a property that has warranted the design of inhibitor-based drugs. At the molecular level, DPP IV cleaves two amino acids from the N-terminus of the intact, biologically active forms of both so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (formerly known as gastric inhibitory polypeptide), resulting in truncated metabolites, which are largely inactive. Inhibition of the enzyme, therefore, is thought to increase levels of the active forms of both incretin hormones, culminating in an increase in insulin release after a meal, in a fully glucose-dependent manner. DPP IV inhibitors combine several features of interest to the drug design process. They can be readily optimised for their target and be designed as low molecular weight, orally active entities compatible with once-daily administration.",
author = "Deacon, {Carolyn F} and Bo Ahr{\'e}n and Holst, {Jens J}",
note = "Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl Peptidases; Enzyme Inhibitors; Humans",
year = "2004",
doi = "10.1517/13543784.13.9.1091",
language = "English",
volume = "13",
pages = "1091--102",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "9",

}

RIS

TY - JOUR

T1 - Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

AU - Deacon, Carolyn F

AU - Ahrén, Bo

AU - Holst, Jens J

N1 - Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl Peptidases; Enzyme Inhibitors; Humans

PY - 2004

Y1 - 2004

N2 - Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabetologists and the pharmaceutical industry alike, as they may become established as the next member of the oral antidiabetic class of therapeutic agents, designed to lower blood glucose and, possibly, prevent the progressive impairment of glucose metabolism in patients with impaired glucose tolerance and Type 2 diabetes. DPP IV has become a focus of attention for drug design, as it has a pivotal role in the rapid degradation of at least two of the hormones released during food ingestion, a property that has warranted the design of inhibitor-based drugs. At the molecular level, DPP IV cleaves two amino acids from the N-terminus of the intact, biologically active forms of both so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (formerly known as gastric inhibitory polypeptide), resulting in truncated metabolites, which are largely inactive. Inhibition of the enzyme, therefore, is thought to increase levels of the active forms of both incretin hormones, culminating in an increase in insulin release after a meal, in a fully glucose-dependent manner. DPP IV inhibitors combine several features of interest to the drug design process. They can be readily optimised for their target and be designed as low molecular weight, orally active entities compatible with once-daily administration.

AB - Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabetologists and the pharmaceutical industry alike, as they may become established as the next member of the oral antidiabetic class of therapeutic agents, designed to lower blood glucose and, possibly, prevent the progressive impairment of glucose metabolism in patients with impaired glucose tolerance and Type 2 diabetes. DPP IV has become a focus of attention for drug design, as it has a pivotal role in the rapid degradation of at least two of the hormones released during food ingestion, a property that has warranted the design of inhibitor-based drugs. At the molecular level, DPP IV cleaves two amino acids from the N-terminus of the intact, biologically active forms of both so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (formerly known as gastric inhibitory polypeptide), resulting in truncated metabolites, which are largely inactive. Inhibition of the enzyme, therefore, is thought to increase levels of the active forms of both incretin hormones, culminating in an increase in insulin release after a meal, in a fully glucose-dependent manner. DPP IV inhibitors combine several features of interest to the drug design process. They can be readily optimised for their target and be designed as low molecular weight, orally active entities compatible with once-daily administration.

U2 - 10.1517/13543784.13.9.1091

DO - 10.1517/13543784.13.9.1091

M3 - Journal article

C2 - 15330741

VL - 13

SP - 1091

EP - 1102

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 9

ER -

ID: 8417357